검색어: difficile (영어 - 몰타어)

difficile colitis
clostridium

clostridium difficile colitis
kolite bi clostridium difficile

clostridium difficile associated diarrhoea
dijarea assoċjata ma’ clostridium difficile

clostridium difficile-associated disease
mard assoċjat ma’ clostridium difficile

uncommon: positive clostridium difficile toxin
mhux komuni: pożittiv għat- tossina tal-clostridium difficile

c. difficile colitis (see section 4.4)
kolite permezz ta ’ c. difficile (ara sezzjoni 4. 4)

uncommon: c. difficile colitis (see section 4.4)
mhux komuni: kolite c. difficile (ara sezzjoni 4.4)

clostridium species (excluding c. difficile)* eubacterium species*
l-ispeċi clostridium (ħlief c. difficile)* l-ispeċi eubacterium

fidaxomicin has been shown to inhibit c. difficile sporulation in vitro.
fidaxomicin wera li jimpedixxi l-isporulazzjoni ta’ c. difficilein vitro.

candida, enterococci and clostridium difficile (see section 4.4).
candida, enterococci u clostridium difficile (ara sezzjoni 4. 4).

dificlir was at least as effective as vancomycin in curing c. difficile infection.
dificlir kien effikaċi tal-inqas daqs il-vankomiċina kontra l-infezzjoni c. difficile.

fidaxomicin is a narrow spectrum antimicrobial drug with bactericidal activity against c. difficile.
fidaxomicin huwa mediċina bi spettru antimikrobijali dejjaq, b’attività batteriċidjali kontra c. difficile.

candidiasis including oropharyngeal and vulvovaginal, clostridium difficile colitis, fungal urinary tract infection
kandidajasi inkluż orofarinġali u vulvovaġinali, kolite bi clostridium difficile, infezzjoni bil-fungu fl-apparat tal- awrina

discontinuation of therapy with invanz and the administration of specific treatment for clostridium difficile should be considered.
għandu jiġi kkunsidrat jekk għandhiex titwaqqaf it-terapija b’invanz u jekk għandhiex tingħata kura speċifika għal clostridium difficile.

appropriate supportive measures, antibiotic treatment of c. difficile, and surgical evaluation should be considered.
miżuri ta’ appoġġ xierqa, kura antibijotika ta’ c. difficile, u evalwazzjoni kirurġika għandhom jiġu kkunsidrati.

pseudomembranous colitis due to clostridium difficile has been reported with doribax and may range in severity from mild to life-threatening.
kolite psewdomembranuża minħabba clostridium difficile kienet irrappurtata b’doribax u s-severità tagħha tista’ tkun minn ħafifa sa waħda ta’ periklu għall-ħajja.

if you get bloody diarrhoea before, during or after your treatment with doribax (clostridium difficile colitis)
jekk ikollok dijarea bid-demm qabel, waqt jew wara l-kura tiegħek b’doribax (clostridium difficile colitis).

in such circumstance, the discontinuation of dalbavancin and the use of supportive measures together with the administration of specific treatment for clostridium difficile should be considered.
f’tali ċirkustanza, il-waqfien ta’ dalbavancin u l-użu ta’ miżuri ta’ appoġġ, flimkien mal-għoti ta’ trattament speċifiku għall-clostridium difficile għandhom jiġu kkunsidrati.

species for which resistance may be a problem acinetobacter species citrobacter species enterobacter species morganella morganii resistant bacteroides fragilis clostridium difficile enterococci listeria monocytogenes proteus vulgaris pseudomonas species serratia species
speċi li għalihom ir- reżistenza tista ’ tkun problema speċi acinetobacter speċi citrobacter speċi enterobacter morganella morganii reżistenti bacteroides fragilis clostridium difficile enterococci listeria monocytogenes proteus vulgaris speċi pseudomonas speċi serratia

clostridium difficile associated diarrhoea (cdad) has been reported for tedizolid phosphate (see section 4.8).
dijarea assoċjata ma’ clostridium difficile (cdad - clostridium difficile associated diarrhoea) ġiet irrapportata għal tedizolid phosphate (ara sezzjoni 4.8).